Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Omeros Corp
(NQ:
OMER
)
3.970
-0.240 (-5.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Omeros Corp
< Previous
1
2
3
Next >
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
October 06, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
October 05, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
October 05, 2021
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Omeros Corporation and Encourages Investors With Losses to Contact the Firm
October 04, 2021
From
The Schall Law Firm
Via
Business Wire
OMER INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation – OMER
October 04, 2021
From
Rosen Law Firm
Via
Business Wire
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
October 01, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports Second Quarter 2021 Financial Results
August 09, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
August 03, 2021
From
Omeros Corporation
Via
Business Wire
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
June 14, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
June 10, 2021
From
Omeros Corporation
Via
Business Wire
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
June 09, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
June 09, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab
May 28, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
May 20, 2021
From
Omeros Corporation
Via
Business Wire
Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress
May 13, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports First Quarter 2021 Financial Results
May 10, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
May 05, 2021
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
May 04, 2021
From
Omeros Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.